SCHEMBL6989974

SCHEMBL6989974

NS(=O)(=O)c1cc(CCNC(=O)/C=C/c2cccs2)ccc1OCCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
POLB P06746 2/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
MAPT P10636 3/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
ALOX5 P09917 1/20 0.44
P2RX4 Q99571 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 3/20 0.43
MMP1 P03956 3/20 0.43
MMP2 P08253 3/20 0.43
MMP9 P14780 3/20 0.43
RECQL P46063 1/20 0.43
ALDH1A1 P00352 3/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
ARG1 P05089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6989982 1.00 SMN1; SMN2 (0.49) SMN1; SMN2POLBMAOAMAOBMAPT
SCHEMBL4703087 0.92 SMN1; SMN2 (0.50) SMN1; SMN2POLBMAOAMAOBMAPT
SCHEMBL4703086 0.92 SMN1; SMN2 (0.50) SMN1; SMN2POLBMAOAMAOBMAPT
SCHEMBL4703089 0.90 POLB (0.50) SMN1; SMN2POLBMAPTHTTKDM4E
SCHEMBL4703090 0.90 POLB (0.50) SMN1; SMN2POLBMAPTHTTKDM4E
SCHEMBL4699948 0.89 MAPT (0.48) SMN1; SMN2POLBMAPTHTTKDM4E
SCHEMBL4699941 0.89 MAPT (0.48) SMN1; SMN2POLBMAPTHTTKDM4E
SCHEMBL6991499 0.88 KDM4E (0.53) SMN1; SMN2POLBMAPTHTTKDM4E
SCHEMBL6991491 0.88 KDM4E (0.53) SMN1; SMN2POLBMAPTHTTKDM4E
SCHEMBL4699317 0.88 POLB (0.45) SMN1; SMN2POLBMAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335902-A1 HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2003-08-20 EP disclosed
US-6472413-B2 FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-10-29 US disclosed
US-20020123495-A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-09-05 US disclosed
WO-2002036565-A1 HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123495-A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them KCNJ11, HCN3, CACNA1E SMN1; SMN2 843/4885POLB 4768/4885MAOA 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.